A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Completed · Phase 2

Conditions studied: Atopic Dermatitis

In brief

A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.

Key facts

Study ID

NCT05717920

Run by

Aldeyra Therapeutics, Inc.

People needed

8

Starts

2023-02-15

Expected to finish

2023-11-21

Last updated by the study team

2024-11-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults ≥18 years of age
• History of atopic dermatitis, according to American Academy of Dermatology criteria, that has been present for at least 6 months
• Mild, moderate, or severe atopic dermatitis, defined as an IGA score of ≥2 at Baseline
• Not pregnant, breastfeeding, or lactating and agree to use a highly effective method of acceptable contraceptive for the trial duration, if applicable

You may not qualify if…

• Presence of clinically significant kidney disease or an estimated gloverular filtration rate (eGFR) of less than or equal to 45 milliliters/min/1.73 m2 during screening
• History of any unstable chronic diseases/conditions, clinically significant abnormalities, or findings, that in the opinion of the Investigator, could compromise subject safety or affect the conduct of the trial

Where it is running

• Bexley Dermatology Research — Bexley, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.